Track the Devyser Diagnostics AB stock price and the full management transaction log of the company, a listed issuer based in Finland. Shares are listed on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, Devyser Diagnostics AB has logged 31 insider filings. Market capitalisation: €989.7m. The latest transaction was reported on 3 September 2026 (Purchase). Among the most active insiders: Mia Arnhult. All data is openly available.
31
Insider Decl.
n/a
Thresholds
€569,201
23 ops.
Buy Volume
n/a
n/a
Sell Volume
43Σ signal
Buys €569,201n/a Sells
Fundamental score
Ranked 21,719 of 29,062 companies
34.7
score / 100
Value
19
Quality
51
FCF yld-6.3%
Earn yld-0.8%
EV/EBITDA37.9x
ROE4.3%
Gross mgn81%
Net mgn-3.4%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
3,000 shares@ €9.45770.031% mcap100.0% of flowAktieISINISIN SE0016588867FI:A003W255-1
25 of 31 declarations
Acerca de Devyser Diagnostics AB
Devyser Diagnostics AB es una empresa centrada en el desarrollo de pruebas de diagnóstico molecular. Se especializa en soluciones para el diagnóstico de enfermedades genéticas y cánceres.